Med Biogene Stock Performance
| MBGNF Stock | USD 0.01 0.00 0.00% |
The company secures a Beta (Market Risk) of 0.0, which conveys not very significant fluctuations relative to the market. the returns on MARKET and Med BioGene are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Med BioGene has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable basic indicators, Med BioGene is not utilizing all of its potentials. The latest stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 79.2 K | |
| Free Cash Flow | -145.1 K |
Med |
Med BioGene Relative Risk vs. Return Landscape
If you would invest 0.59 in Med BioGene on September 30, 2025 and sell it today you would earn a total of 0.00 from holding Med BioGene or generate 0.0% return on investment over 90 days. Med BioGene is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded pink sheets are less volatile than Med, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Med BioGene Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Med BioGene's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Med BioGene, and traders can use it to determine the average amount a Med BioGene's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| MBGNF |
Based on monthly moving average Med BioGene is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Med BioGene by adding Med BioGene to a well-diversified portfolio.
Med BioGene Fundamentals Growth
Med Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Med BioGene, and Med BioGene fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Med Pink Sheet performance.
| Return On Asset | -2.48 | |||
| Current Valuation | 251.67 K | |||
| Shares Outstanding | 17.26 M | |||
| Price To Earning | (3.33) X | |||
| EBITDA | (59.96 K) | |||
| Cash And Equivalents | 38.6 K | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (145.12 K) | |||
| Earnings Per Share | (0) X | |||
| Total Asset | 10.79 K | |||
About Med BioGene Performance
By analyzing Med BioGene's fundamental ratios, stakeholders can gain valuable insights into Med BioGene's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Med BioGene has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Med BioGene has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Previously, it was engaged in the life science business with a focus on the development and commercialization of genomic-based clinical tests for non-small-cell lung cancer. Med BioGene Inc. was incorporated in 2006 and is headquartered in Vancouver, Canada. Med Biogene operates under Diagnostics Research classification in the United States and is traded on OTC Exchange.Things to note about Med BioGene performance evaluation
Checking the ongoing alerts about Med BioGene for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Med BioGene help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Med BioGene generated a negative expected return over the last 90 days | |
| Med BioGene has some characteristics of a very speculative penny stock | |
| Med BioGene has a very high chance of going through financial distress in the upcoming years | |
| The company has a current ratio of 0.55, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Med BioGene until it has trouble settling it off, either with new capital or with free cash flow. So, Med BioGene's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Med BioGene sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Med to invest in growth at high rates of return. When we think about Med BioGene's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (59.96 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| Med BioGene has accumulated about 38.6 K in cash with (145.12 K) of positive cash flow from operations. | |
| Roughly 49.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Med BioGene's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Med BioGene's stock is overvalued or undervalued compared to its peers.
- Examining Med BioGene's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Med BioGene's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Med BioGene's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Med BioGene's pink sheet. These opinions can provide insight into Med BioGene's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Med Pink Sheet analysis
When running Med BioGene's price analysis, check to measure Med BioGene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Med BioGene is operating at the current time. Most of Med BioGene's value examination focuses on studying past and present price action to predict the probability of Med BioGene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Med BioGene's price. Additionally, you may evaluate how the addition of Med BioGene to your portfolios can decrease your overall portfolio volatility.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Stocks Directory Find actively traded stocks across global markets | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |